Skip to content

Efficacy of individualized location-based repetitive transcranial magnetic stimulation in the treatment of migraine: a prospective clinical study

Efficacy of individualized location-based repetitive transcranial magnetic stimulation in the treatment of migraine: a prospective clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110115
Enrollment
Unknown
Registered
2025-09-30
Start date
2025-09-30
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Interventions

Individual localization therapy group:Individual orientation
Traditional localization therapy group:Traditional localization

Sponsors

The First Affiliated Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.18-65 years old; Both men and women; 2.Patients diagnosed with migraine according to the International Classification of Headache Disorders (ICHD-III) , first onset before age 50, and a history of migraine >1 year; 3.>=4 days per month in the 3 months before the screening period and during the screening period; 4.Informed consent documents are signed, subjects cooperate to complete the assessment and rTMS treatment, and are informed of any known and potential risks and available alternative treatments.

Exclusion criteria

Exclusion criteria: 1.Patients with TMS contraindications (metal implants, pacemakers, etc.); 2.Severe anxiety and depression due to various reasons (24 HAMD scores greater than 35, 14 HAMA scores greater than 29); 3.History of migraine prophylactic drug adjustment during screening and treatment; 4.aphasia and cognitive dysfunction (MMSE rating <=23); 5.Pregnancy or lactation; 6.Clinicians evaluate severe comorbidities that are not treatable.

Design outcomes

Primary

MeasureTime frame
Change in the average number of migraine days per month;

Secondary

MeasureTime frame
Change in the average number of migraine days per month;Migraine severity;Metabolomics;Changes of FMRI at rest state;Cytokines;Accompanying symptoms;Medication;Anxiety and depression;Intestinal flora;Migraine score,;

Countries

China

Contacts

Public ContactFeng Zhiying

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

fzy1972@zju.edu.cn+86 591 8823 5148

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026